Gesponsert
'Roche could've earned over 100 times what it cost for rare disease drug'
Posted
Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful projects and ongoing research. While the drug remains unaffordable for many in India, Roche offers access programs and free treatment to some patients.
Search
Nach Verein filtern
- National
- International
- Business
- Technology
- Health
- Ausbildung
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
Read More
'Desh se badhkar kuch nahi hota': Shikhar Dhawan boycotts IND vs PAK clash
Shikhar Dhawan has withdrawn from the India vs Pakistan match in the World Championship of...
Yuzvendra-Mahvash holiday in London; fuel dating rumours
Cricketer Yuzvendra Chahal and RJ Mahvash are fueling dating rumors after being spotted together...
© 2025 Dununu.com : Circle of Life - Santan Social Network
Deutsch
